Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.70 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.70 |
| ▸ | HPGD | P15428 | 1/20 | 0.70 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.70 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.61 |
| ▸ | EGFR | P00533 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 3/20 | 0.55 |
| ▸ | POLB | P06746 | 2/20 | 0.55 |
| ▸ | GFER | P55789 | 1/20 | 0.55 |
| ▸ | ALPL | P05186 | 1/20 | 0.53 |
| ▸ | ALPI | P09923 | 1/20 | 0.53 |
| ▸ | ALPG | P10696 | 1/20 | 0.53 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.53 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | MPL | P40238 | 2/20 | 0.43 |
| ▸ | NSD2 | O96028 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dobesilic Acid SCHEMBL27703351 | 0.98 | LMNA (0.68) | LMNAHSD17B10HPGDHIF1APTGS1 | |
| Dobesilic Acid SCHEMBL27703352 | 0.98 | LMNA (0.68) | LMNAHSD17B10HPGDHIF1APTGS1 | |
| Dobesilic Acid SCHEMBL27527255 | 0.98 | HSD17B10 (0.68) | LMNAHSD17B10HPGDHIF1APTGS1 | |
| Dobesilic Acid SCHEMBL232087 | 0.98 | LMNA (0.72) | LMNAHSD17B10HPGDHIF1APTGS1 | |
| Dobesilic Acid SCHEMBL29389625 | 0.98 | LMNA (0.72) | LMNAHSD17B10HPGDHIF1APTGS1 | |
| Dobesilic Acid SCHEMBL214799 | 0.95 | LMNA (0.70) | LMNAHSD17B10HPGDHIF1APTGS1 | |
| Dobesilic Acid SCHEMBL78224 | 0.95 | LMNA (0.70) | LMNAHSD17B10HPGDHIF1APTGS1 | |
| Dobesilic Acid SCHEMBL10589964 | 0.95 | HSD17B10 (0.70) | LMNAHSD17B10HPGDHIF1APTGS1 | |
| Dobesilic Acid SCHEMBL15364076 | 0.95 | LMNA (0.70) | LMNAHSD17B10HPGDHIF1APTGS1 | |
| Dobesilic Acid SCHEMBL9790423 | 0.95 | LMNA (0.70) | LMNAHSD17B10HPGDHIF1APTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 196 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118324467-A | Counterweight cementing material applied to counterweight concrete | 中铁十七局集团第六工程有限公司 | 2024-07-12 | — | — | CN | claimed |
| CN-117276800-A | Preparation of single-ion polymer nanofiber surface modified polypropylene film and lithium metal battery | 山东正熵能源科技有限公司 | 2023-12-22 | — | — | CN | claimed |
| CN-116845337-A | Sp (sp) 3 Hybrid boron-based single-ion polymer lithium salt DDBSB-Li, and preparation method and application thereof | 山东正熵能源科技有限公司 | 2023-10-03 | — | — | CN | claimed |
| CN-116751345-A | Early-strength polycarboxylate superplasticizer and preparation method and application thereof | 辽宁省交通规划设计院有限责任公司 | 2023-09-15 | — | — | CN | claimed |
| CN-115819290-A | Preparation method of 2, 5-dihydroxy benzene sulfonic acid calcium monohydrate | 中楚鑫新材料科技(荆州)有限公司 | 2023-03-21 | — | — | CN | claimed |
| CN-113429564-A | Modified polyether-ether-ketone resin capable of being rapidly photocrosslinked, and preparation method and application thereof | 广东工业大学 | 2021-09-24 | — | — | CN | claimed |
| US-20180078495-A1 | Skin Penetration Enhancing Systems for Polar Drugs | DERMACT PHARMACEUTICAL, INC. | 2018-03-22 | — | — | US | claimed |
| US-20170231932-A1 | METHODS OF USE FOR 2,5-DIHYDROXYBENZENE SULFONIC ACID COMPOUNDS FOR THE TREATMENT OF CANCER, ROSACEA AND PSORIASIS | AmDerma Pharmaceuticals, LLC | 2017-08-17 | — | — | US | claimed |
| US-9610256-B2 | Methods of use for 2,5-dihydroxybenzene sulfonic acid compounds for the treatment of cancer | AmDerma Pharmaceuticals, LLC (US) | 2017-04-04 | — | — | US | claimed |
| US-9301931-B2 | Methods of use for 2,5-dihydroxybenzene sulfonic acid compounds for the treatment of cancer, rosacea and psoriasis | AmDerma Pharmaceuticals, LLC (US) | 2016-04-05 | — | — | US | claimed |
| EP-0954298-B1 | 2,5-DIHYDROXYBENZENESULFONIC DERIVATIVES FOR THE TREATMENT OF SEXUAL DYSFUNCTION | ESTEVE LABOR DR (ES) | 2006-03-08 | — | — | EP | claimed |
| EP-1596850-A1 | USE OF 2,5-DIHYDROXYBENZENESULFONIC COMPOUNDS FOR THE TREATMENT OF DISORDERS BASED ON AN IMPAIRMENT OF NO PRODUCTION AND/OR OF REGULATION OF EDHF FUNCTION | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2005-11-23 | — | — | EP | claimed |
| EP-1565174-A1 | USE OF 2,5-DIHYDROXYBENZENESULFONIC COMPOUNDS FOR THE TREATMENT OF DISORDERS BASED ON AN IMPAIRMENT OF NO PRODUCTION AND/OR OF REGULATION OF EDHF FUNCTION | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2005-08-24 | — | — | EP | claimed |
| WO-2005013962-A1 | ACTIVE SUBSTANCE COMBINATION COMPRISING A 2,5-DIHYDROXYBENZENESULFONIC COMPOUND AND A POTASSIUM ION CHANNEL MODULATOR | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2005-02-17 | — | — | WO | claimed |
| CN-1552348-A | Sedinafine composition and its use | 上海华拓医药科技发展有限公司 | 2004-12-08 | — | — | CN | claimed |
| WO-2004050075-A1 | USE OF 2,5-DIHYDROXYBENZENESULFONIC COMPOUNDS FOR THE TREATMENT OF DISORDERS BASED ON AN IMPAIRMENT OF NO PRODUCTION AND/OR OF REGULATION OF EDHF FUNCTION | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2004-06-17 | — | — | WO | claimed |
| WO-2004050074-A1 | USE OF 2,5-DIHYDROXYBENZENESULFONIC COMPOUNDS FOR THE TREATMENT OF DISORDERS BASED ON AN IMPAIRMENT OF NO PRODUCTION AND/OR OF REGULATION OF EDHF FUNCTION | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2004-06-17 | — | — | WO | claimed |
| US-6403643-B1 | ADMINISTERING CALCIUM DOBESILATE, ETHAMSYLATE, AND PERSILATE FOR THE TREATMENT OF VASCULAR DISORDERS AND SEXUAL DYSFUNCTION | LABORATORIES DEL DR. ESTEVE, S.A. (ES) | 2002-06-11 | — | — | US | claimed |
| US-6147112-A | ADMINISTERING TO TREAT SEXUAL AND VASCULAR DISORDERS AND DIABETES | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2000-11-14 | — | — | US | claimed |
| US-4511557-A | CALF'S BLOOD DIAYSATE AS VASODILATION POTENTIATOR | GAURI KAILASH KUMAR (DE) | 1985-04-16 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170231932-A1 | METHODS OF USE FOR 2,5-DIHYDROXYBENZENE SULFONIC ACID COMPOUNDS FOR THE TREATMENT OF CANCER, ROSACEA AND PSORIASIS | IL2, IL2RA, IL5 | LMNA 4181/4885HSD17B10 1497/4885HPGD 2149/4885 |
| US-20180078495-A1 | Skin Penetration Enhancing Systems for Polar Drugs | ABCB11, KCNK5, KCNQ5 | LMNA 3019/4885HSD17B10 2486/4885HPGD 2531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.